Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells

Immunology

Volumn 146, Issue 2, 2015, Pages 327-338

  Thomann, Sabrina ^a   Boscheinen, Jan B ^a   Vogel, Karin ^a   Knipe, David M ^b   DeLuca, Neal ^c   Gross, Stefanie ^d   Schuler Thurner, Beatrice ^d   Schuster, Philipp ^e   Schmidt, Barbara ^a,e  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cancer; Cytotoxicity; Dendritic cells; Human; Viral

Indexed keywords

ALPHA INTERFERON RECEPTOR; GRANZYME B; HERPES SIMPLEX VIRUS 1 D 106S; INTERFERON; ONCOLYTIC HERPES VIRUS; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CANCER VACCINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL FRACTIONATION; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; NATURAL KILLER CELL; ONCOLYTIC VIROTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SUPERNATANT; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CYTOTOXICITY; DENDRITIC CELL; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LEUKEMIA; METABOLISM; NECROSIS; PATHOGENICITY; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS; TIME FACTOR; TRANSPLANTATION; TUMOR CELL LINE; VIROLOGY;

APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE I; LEUKEMIA; MELANOMA; NECROSIS; SKIN NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84941619774     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12509     Document Type: Article

References (49)

1. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012; 62:118-28.
2. Agarwala SS, Kirkwood JM. Interferons in melanoma. Curr Opin Oncol 1996; 8:167-74.
3. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 2010; 74:27-39.
4. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009; 19:275-82.
5. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58:1-14.
6. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008; 66:118-34.
7. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23:5779-87.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
9. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-51.
10. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 5:919-23.
11. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-7.
12. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989-2003.
13. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, et al. Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33:1052-62.
14. + T cell activation in vivo. J Immunol 2008; 181:3811-7.
15. Di Pucchio T, Chatterjee B, Smed-Sorensen A, Clayton S, Palazzo A, Montes M, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008; 9:551-7.
16. Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F, et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013; 19:1147-58.
17. Hoeffel G, Ripoche AC, Matheoud D, Nascimbeni M, Escriou N, Lebon P, et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007; 27:481-92.
18. + T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2013; 121:459-67.
19. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007; 178:1534-41.
20. Chaperot L, Blum A, Manches O, Lui G, Angel J, Molens JP, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006; 176:248-55.
21. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-85.
22. + human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity. J Immunol 2012; 188:1583-91.
23. de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol 2011; 48:810-7.
24. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75.
25. Schuster P, Donhauser N, Pritschet K, Ries M, Haupt S, Kittan NA, et al. Co-ordinated regulation of plasmacytoid dendritic cell surface receptors upon stimulation with herpes simplex virus type 1. Immunology 2010; 129:234-47.
26. Liu X, Broberg E, Watanabe D, Dudek T, Deluca N, Knipe DM. Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine 2009; 27:2760-7.
27. Strasser EF, Weidinger T, Zimmermann R, Ringwald J, Eckstein R. Recovery of white blood cells and platelets from leukoreduction system chambers of Trima Accel and COBE Spectra plateletpheresis devices. Transfusion 2007; 47:1943-4 author reply 4-5.
28. Vogel K, Thomann S, Vogel B, Schuster P, Schmidt B. Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human HSV-1 infections. Immunology 2014; 132:588-600.
29. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72:3307-20.
30. Kittan NA, Bergua A, Haupt S, Donhauser N, Schuster P, Korn K, et al. Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis. J Immunol 2007; 179:4219-30.
31. Schaber B, Mayer P, Schreiner T, Rassner G, Fierlbeck G. Anti-proliferative activity of natural interferon-α, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Res 1994; 4:319-26.
32. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32.
33. Aspord C, Tramcourt L, Leloup C, Molens JP, Leccia MT, Charles J, et al. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization. J Invest Dermatol 2014; 134:2551-61.
34. Tel J, Anguille S, Waterborg CE, Smits EL, Figdor CG, de Vries IJ. Tumoricidal activity of human dendritic cells. Trends Immunol 2014; 35:38-46.
35. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70.
36. Chisholm SE, Howard K, Gomez MV, Reyburn HT. Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J Infect Dis 2007; 195:1160-8.
37. Fitzgerald-Bocarsly P, Howell DM, Pettera L, Tehrani S, Lopez C. Immediate-early gene expression is sufficient for induction of natural killer cell-mediated lysis of herpes simplex virus type 1-infected fibroblasts. J Virol 1991; 65:3151-60.
38. Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P, et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 2007; 125:184-93.
39. Aspord C, Leccia MT, Charles J, Plumas J. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res 2013; 1:402-15.
40. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200:255-68.
41. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118:1165-75.
42. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173:3051-61.
43. Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 2004; 103:2162-9.
44. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763-71.
45. Kaur A, Sanford HB, Garry D, Lang S, Klumpp SA, Watanabe D, et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 2007; 357:199-214.
46. Murphy CG, Lucas WT, Means RE, Czajak S, Hale CL, Lifson JD, et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000; 74:7745-54.
47. Lui G, Manches O, Angel J, Molens JP, Chaperot L, Plumas J. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS ONE 2009; 4:e7111.
48. Speeckaert R, van Geel N, Vermaelen KV, Lambert J, Van Gele M, Speeckaert MM, et al. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2011; 24:334-44.
49. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-5.